|Mr. Michael G. Grey||Executive Chairman||70k||N/A||1953|
|Dr. Javier Szwarcberg M.D., M.P.H.||CEO & Director||693.9k||N/A||1970|
|Mr. Samir M. Gharib CPA, M.B.A.||President & CFO||536.13k||N/A||1982|
|Dr. Ralph William Charlton III, M.D.||Chief Medical Officer||436.38k||N/A||1970|
|Ms. P. J. Ramtin||Senior Vice President of Business Operations||N/A||N/A||N/A|
|Ms. Heidi Petersen M.P.H.||Senior Vice President of Regulatory & Quality||N/A||N/A||N/A|
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.
Spruce Biosciences, Inc.’s ISS governance QualityScore as of 28 November 2023 is 10. The pillar scores are Audit: 9; Board: 9; Shareholder rights: 8; Compensation: 9.